Skip to main content
  • Register
  • Help
  • Contact us
  • Log out of your HL account

Dexcom Inc (DXCM) Common Stock USD0.001

Sell:$278.25 Buy:$278.61 Change: No change
NASDAQ:2.29%
Prices delayed by at least 15 minutes | Switch to live prices |
Sell:$278.25
Buy:$278.61
Change: No change
Prices delayed by at least 15 minutes | Switch to live prices |
Sell:$278.25
Buy:$278.61
Change: No change
Prices delayed by at least 15 minutes | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Dexcom, Inc. (Dexcom) is a medical device company. The Company is focused on the design, development and commercialization of continuous glucose monitoring (CGM) systems for ambulatory use by people with diabetes and for use by healthcare providers. The Company's products consist of DexCom G4 PLATINUM and DexCom G5 Mobile. The Company is commercializing its fifth generation CGM system. The Company's markets DexCom G4 PLATINUM under a Conformite Europeenne Marking (CE Mark), in the European Union, Australia, New Zealand and the countries in Asia and Latin America, and in the United States with approval from the United States Food and Drug Administration (FDA). The DexCom G4 PLATINUM with Share remote monitoring system uses a wireless connection between a patient's receiver and an application on the patient's iPhone, iPod touch, or iPad to transmit glucose information to applications on the mobile devices of designated recipients (followers).

Contact details

Address:
6340 Sequence Dr
SAN DIEGO
92121-4356
United States
Telephone:
+1 (858) 2000200
Website:
www.dexcom.com

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
DXCM
ISIN:
US2521311074
Market cap:
$26.01 billion
Shares in issue:
91.59 million
Sector:
Health Care Equipment
Exchange:
NASDAQ
Country:
United States
Currency:
US dollar
Indices:
NASDAQ Comb. Composite

Key personnel

  • Kevin Sayer
    Chairman of the Board, President, Chief Executive Officer
  • Quentin Blackford
    Chief Financial Officer, Chief Operating Officer, Principal Accounting Officer, Principal Financial Officer
  • Jake Leach
    Executive Vice President, Chief Technology Officer
  • Donald Abbey
    Executive Vice President - Quality and Regulatory Affairs
  • Andrew Balo
    Executive Vice President - Regulatory Strategy, Clinical Affairs, and Strategic Partnership Development
  • Richard Doubleday
    Executive Vice President, Chief Commercial Officer
  • Steven Pacelli
    Executive Vice President - Strategy and Corporate Development
  • Patrick Murphy
    Senior Vice President, Chief Compliance Officer, General Counsel
  • Heather Ace
    Senior Vice President - Human Resources
  • Jeffrey Moy
    Senior Vice President - Operations

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.

Share

The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.